A Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients With Alpha-1 Antitrypsin Deficiency (AATD)
Conditions
Alpha 1-Antitrypsin Deficiency
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Clinical Study Center, Birmingham, Alabama, United States
Clinical Study Center, Boston, Massachusetts, United States
Clinical Study Center, Charleston, South Carolina, United States
Clinical Study Center, Adelaide, Australia
Clinical Study Center, Fitzroy, Australia
Clinical Study Center, Dublin, Ireland
Clinical Study Center, Leiden, Netherlands
Clinical Study Center, Auckland, New Zealand
Clinical Study Center, Hamilton, New Zealand
Clinical Study Center, London, United Kingdom
Clinical Study Center, Southampton, United Kingdom
Study leads
Medical Information
Study Director
Beam Therapeutics